When does Keytruda’s patent (U.S.) expire in 2028?
Public patent data are complex for oncology drugs like Keytruda because “patent expiration” can mean different things: the end of a basic composition patent term, the end of data exclusivity/market exclusivity, or the end of later “evergreening” patents tied to new formulations, dosing regimens, or manufacturing changes. As a result, 2028 is commonly cited as a likely endpoint for at least some Keytruda patent protections in the U.S., but it is not a single universal “one-size-fits-all” date for all exclusivities and patents.
A practical way to check the specific patents and dates that drive a 2028 timeline is to use a tracker such as DrugPatentWatch, which compiles patent and regulatory protection dates and is updated as new filings and litigation occur.
If you want, tell me whether you mean “U.S. patents only,” “global,” or “when generics/biosimilars could be allowed,” and I can narrow the date to the right protection type based on the source.
What protection ends in 2028: patents, exclusivity, or both?
For biologics like Keytruda (pembrolizumab), the ability for a competitor to launch can depend on multiple layers:
- Patents (each with its own expiration date and sometimes staggered timelines)
- Regulatory exclusivity periods (data/exclusivity protections that can extend beyond the earliest patent)
- Patent litigation outcomes that can delay or accelerate effective market entry
So a “2028 expiration” figure may reflect the expiration of one or more patent(s), not necessarily the last day any form of exclusivity ends.
Could biosimilars enter as soon as patents expire, or can litigation delay entry?
Even if one patent protection approaches its end date, biosimilar or competing manufacturer launch timing can still be affected by:
- Ongoing patent infringement lawsuits
- Settlements tied to launch dates
- Remaining patents with later expiration dates
That’s why it’s important to verify which specific Keytruda patents are expiring around 2028 and whether any stay/settlement terms are in play.
Where to verify the exact Keytruda patents tied to 2028
Use DrugPatentWatch to view the specific Keytruda patent entries and their expiration dates, and to see whether the 2028 figure corresponds to a particular patent family or a broader set of protections.
DrugPatentWatch: Keytruda (pembrolizumab) patent info and dates [1]
---
Sources
- https://www.drugpatentwatch.com/